[{"NetIncomeLossConverted_1_Q2_USD":-44299000.0,"NetIncomeLossConverted_2_Q2_USD":-81475000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-71327000.0,"CommonStockSharesOutstanding_0_Q2_shares":73576989.0,"StockholdersEquity_0_Q2_USD":685006000.0,"EarningsPerShareBasic_1_Q2_USD":-0.6,"EarningsPerShareBasic_2_Q2_USD":-1.13,"RevenuesConverted_1_Q2_USD":8698000.0,"RevenuesConverted_2_Q2_USD":18829000.0,"Assets_0_Q2_USD":774046000.0,"CommonStockSharesConverted_0_Q2_shares":73576989.0,"Ticker":"RVMD","CIK":"1628171","name":"REVOLUTION MEDICINES, INC.","OfficialName":"Revolution Medicines Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1775342076.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20210811"}]